Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria
Open Access
- 17 November 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (22) , 11124
Abstract
The emergence of drug resistance remains a major challenge in the treatment of tuberculosis and other mycobacterial infections. To combat the rise in resistance, strategies that reduce the frequency of resistance mutations are urgently needed. Verapamil is a small-molecule compound that can enhance the potency of companion drugs in combination regimen. Here, we investigate if verapamil can decrease the resistance frequency of antimycobacterial drugs. The results show that verapamil significantly reduces the resistance frequency of multiple antimycobacterial agents, including the DNA gyrase inhibitor moxifloxacin, the protein synthesis inhibitor streptomycin, and the RNA polymerase inhibitor rifampicin in Mycobacterium smegmatis. The presence of point mutations in the target was confirmed for moxifloxacin-resistant M. smegmatis. Suppression of resistance evolution against moxifloxacin by verapamil was also found in the slow-growing, pathogenic mycobacteria M. avium and M. tuberculosis. Real-time qPCR analysis in M. smegmatis showed that verapamil treatment downregulates the expression of multiple efflux pump genes and upregulates DNA repair genes. These findings suggest that verapamil exerts a dual role by interfering with efflux pump functionality and by reducing the probability of chromosomal mutations. The combination of these properties may underlie the promise of verapamil as adjuvant to enhance the effectiveness of current antimycobacterial chemotherapy.Keywords
Funding Information
- China Scholarship Council
This publication has 57 references indexed in Scilit:
- A potent phenylalkylamine disrupts mycobacterial membrane bioenergetics and augments bactericidal activity of bedaquilineiScience, 2025
- A Dose‐Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in TuberculosisClinical Pharmacology & Therapeutics, 2023
- Investigation of efflux pump genes in isoniazid resistant Mycobacterium tuberculosis isolatesIndian Journal of Medical Microbiology, 2023
- Efflux-linked accelerated evolution of antibiotic resistance at a population edgeMolecular Cell, 2022
- Spontaneous mutations conferring antibiotic resistance to antitubercular drugs at a range of concentrations in Mycobacterium smegmatisDrug Development Research, 2018
- Mycobacterium tuberculosis Major Facilitator Superfamily TransportersThe Journal of Membrane Biology, 2017
- Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalinBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2014
- Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux MechanismCell, 2011
- Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacinVeterinary Microbiology, 2011
- Mycobacterium tuberculosis ΔRD1 ΔpanCD: A safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosisVaccine, 2006